Soligenix Inc. (NASDAQ: SNGX) Advances CiVax Amid Ongoing COVID-19 Threat
An increase in deaths from COVID-19 underscores the persistent danger of the virus and the urgent need for effective protective measures and treatments. Soligenix is addressing this need through the development of CiVax, its proprietary, heat-stable COVID-19 subunit vaccine candidate. Recent preclinical studies have demonstrated that CiVax can induce rapid and broad protection against multiple COVID-19 variants. Despite the passage of time since the pandemic, COVID-19 continues to pose a significant global health threat. Recent data from the World Health Organization (“WHO”) indicates that during the 28-day period from Jan. 6 to Feb. 2, 2025, more than 147,000 new COVID-19 cases…